181 results
8-K
EX-99
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
12 Apr 02
Other events
12:00am
diabetes, dyslipidemias and associated
cardiovascular disorders. Lilly's expertise and leadership in these fields
ensures leverage … leadership
position in gene transcription technology, primarily related to Intracellular
Receptors (IRs) and Signal Transducers and Activators
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
18 Apr 11
Ligand Names Matthew W. Foehr Chief Operating Officer
12:00am
in Biology from Santa Clara University.
“Matt has tremendous experience and is uniquely qualified to assume this senior leadership role at Ligand,” said … to providing executive leadership at Ligand, Matt will help develop strategy, cultivate new customer and partner relationships, and engage
8-K
EX-99
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 May 07
Termination of a Material Definitive Agreement
12:00am
to the management team will provide new financial and accounting
leadership at this important time for Ligand as we move through our activities … are based on its leadership
position in gene transcription technology, primarily related to intracellular
receptors.
Forward-Looking Statements
8-K
EX-99
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
5 Mar 07
Entry into a Material Definitive Agreement
12:00am
and expertise to our Board, and I look forward to
working with them. The company will also benefit from the leadership and
experience of Dr. Kozarich in his … leadership
position in gene transcription technology, primarily related to Intracellular
Receptors.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
425
EX-99.2
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
23 Mar 22
Business combination disclosure
5:29pm
(transgenic rat, $115 million of fully-committed equity financing provided to mouse and chicken, and cow-derived) OmniAb Scientific leadership in antibody … 3 programs from recent Merck collaboration.
8 EXPERIENCED LEADERSHIP TEAM WITH PROVEN TRACK RECORD OF SUCCESS OmniAb Leadership Team Avista
8-K
EX-99.2
uwslfpyhjfq4gpkg
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
424B3
ow8w26c
16 Jan 07
Prospectus supplement
12:00am
8-K
EX-99
fagl2vahx qe47h3
12 Sep 03
Other events
12:00am
8-K
EX-99.1
7y2vqln7pqyf5ib5a
31 Oct 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
7j9v fdaantw9
24 Sep 08
1 Joseph A. Mollica, Ph.D., Chairman of the Board, Interim President & CEO, Pharmacopeia John L. Higgins, President & CEO
12:00am
425
EX-99.1
k8498lnulgg g4m6
25 Sep 08
Business combination disclosure
12:00am
425
EX-99.2
wdr46kedwag 29vs2hgc
24 Sep 08
Business combination disclosure
12:00am
8-K
EX-99
85x ou9zgg
11 Aug 04
Other events
12:00am
8-K
EX-99
tpe1f59douhpfpy4
2 Oct 06
Departure of Directors or Principal Officers
12:00am
8-K
EX-99
y5im416z5j
12 Jun 06
Other Events
12:00am
8-K
EX-99.1
kjwfjr46 vay3joh
24 Dec 08
Ligand Completes Pharmacopeia Acquisition
12:00am
8-K
EX-99.1
brq53mr7o1kh5
8 Jan 01
Current report
12:00am
8-K
EX-99.1
xm79y
4 Aug 08
Ligand Pharmaceuticals Appoints Dr. Stephen Sabba to Board of Directors
12:00am
8-K
EX-99.2
ab8g7 lmscvq
2 Apr 02
Other events
12:00am
8-K
EX-99.1
zg0ntawxu5re
2 Apr 03
Other events
12:00am